Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076995 | 0.81 | CHEK1 (0.48) | ABL1BCRCHEK1LRRK2 | |
| SCHEMBL2079417 | 0.81 | ABL1 (0.38) | ABL1BCRCHEK1 | |
| SCHEMBL2075089 | 0.80 | RET (0.43) | ABL1BCRCHEK1LRRK2 | |
| SCHEMBL2079322 | 0.80 | PDE9A (0.37) | ABL1BCR | |
| SCHEMBL2076741 | 0.79 | RET (0.42) | ABL1BCRCHEK1LRRK2 | |
| SCHEMBL2078784 | 0.79 | PDE9A (0.37) | ABL1BCR | |
| SCHEMBL3767471 | 0.78 | ABL1 (0.36) | ABL1BCRCHEK1 | |
| SCHEMBL2076232 | 0.77 | ABL1 (0.37) | ABL1BCRCHEK1 | |
| SCHEMBL2078780 | 0.76 | ABL1 (0.38) | ABL1BCRCHEK1 | |
| SCHEMBL2077565 | 0.76 | ABL1 (0.36) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101448822-B | Substituted pyrazolopyrimidines | CEPHALON INC | 2013-11-06 | — | — | CN | claimed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | claimed |
| CN-101448822-B | Substituted pyrazolopyrimidines | CEPHALON INC | 2013-11-06 | — | — | CN | disclosed |
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2351751-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| CN-101448822-A | Substituted pyrazolopyrimidines | KYOCERA CORP (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2024360-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | Cephalon, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | ABL1 2806/4885BCR 3149/4885CHEK1 1661/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | ABL1 2258/4885BCR 3103/4885CHEK1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.